SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

NuCana plc NCNA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • GB • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

NuCana plc (NCNA) is a Biotechnology company in the Healthcare sector, currently trading at $2.18. It has a SharesGrow Score of 49/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Valuation: NCNA trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25).

Net income is $29M (loss), growing at -2.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $674,811 against $24M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 5.6 (strong liquidity). Debt-to-assets is 2.3%. Total assets: $30M.

Analyst outlook: 7 / 8 analysts rate NCNA as buy (88%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 67/100 (Partial), Moat 28/100 (Fail), Future 90/100 (Pass), Income ?/100 (Fail).

NCNA SharesGrow Score Overview

60/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 15/100

Financials — average growth

PAST 0/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 28/100

Gross margin is + market cap

FUTURE 90/100

Analyst outlook — as buy

INCOME 0/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — NCNA

NCNA trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25). Trailing PEG 0.02. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

NCNA: +0%/yr revenue is, -2.1%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

No analyst coverage available for this stock.

Balance sheet NCNA: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 5.6 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

NCNA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.

View details →

Analyst outlook: 7 / 8 analysts rate NCNA as buy (88%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

No analyst coverage available for this stock.

Stock Chart & Stats

Market Data

52-Week Range1.33-250

Volume24.51K

Avg Volume (30D)53.56K

Market Cap$13.24M

Beta (1Y)1.80

Share Statistics

EPS (TTM)-7.75

Shares Outstanding$3.7M

IPO Date2017-09-28

Employees20

CEOHugh Stephen Griffith

Financial Highlights & Ratios

Gross Profit$-267.99K

EBITDA$-20.09M

Net Income$-28.71M

Operating Income$-20.38M

Total Cash$24.21M

Total Debt$674.81K

Net Debt$-23.53M

Total Assets$29.78M

Price / Earnings (P/E)-0.3

Analyst Forecast

Rating ConsensusBuy

Analysts Covering8

Buy 88% Hold 13% Sell 0%

Company Info

CountryGB

ExchangeNASDAQ Global Select

CurrencyUSD

ISINUS67022C3043

Price Chart

NCNA

NuCana plc ↗ · NASDAQ Global Select

Healthcare • Biotechnology

1.33 52WK RANGE 250.00

People Also View

Cidara Therapeutics, Inc.

Day One Biopharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc.

CytomX Therapeutics, Inc.

Zura Bio Limited

Silence Therapeutics plc

Inozyme Pharma, Inc.

Acumen Pharmaceuticals, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message